IHC Dec 7, 2022 Enhertu Shows Activity in Early-Stage HER2-Low Breast Cancer Patients in Study Reported at SABCS Dec 1, 2022 Nectin Therapeutics Enters Clinical Stage With Drug for Non-Responders to Checkpoint Inhibitors Premium Nov 23, 2022 Higher TIL Levels in Residual Disease May Predict Worse Survival in HER2-Positive Breast Cancer Premium Nov 18, 2022 NeoGenomics, ImmunoGen Ink Testing Deal for Newly Approved Folate Receptor Drug Nov 15, 2022 FDA Approves ImmunoGen's Elahere for Folate Receptor Alpha-Positive Ovarian Cancer Oct 27, 2022 Immunotherapy Response Features Identified in Pancreatic Cancer Microenvironment Oct 5, 2022 Massive Bio, Perthera Partner on Biomarker-Based Clinical Trial Matching Sep 28, 2022 Cofactor Genomics RNA-seq Assay Outperforms PD-L1 IHC to Predict Immunotherapy Responders Premium Sep 11, 2022 Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients Premium Aug 8, 2022 CAP Weighs in on dMMR, MSI Assays for Immunotherapy Patient Selection Premium Jul 27, 2022 Celularity Begins Trial of NK Cell Therapy, Herceptin, Keytruda for HER2-Positive Gastric Cancer Jul 12, 2022 NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling Jun 22, 2022 Daiichi Sankyo's Application for Enhertu in HER2-Low Breast Cancer to Commence European Review Jun 9, 2022 Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients Jun 8, 2022 Biomarker-Defined Subset of Early Breast Cancer Patients Can Avoid Radiation, ASCO Data Show Jun 6, 2022 With ASCO Data, Novartis' Tafinlar-Mekinist Heads Toward FDA for BRAF-Mutant Pediatric Brain Cancer Premium Jun 6, 2022 Enhertu Benefit in HER2-Low Breast Cancer Wows at ASCO; Signals Shifting Therapy, Dx Paradigms May 26, 2022 UK Researchers ID Potential Biomarker of Response to Herceptin in Overweight Breast Cancer Patients Premium Mar 25, 2022 Study Shows TIL-Based Biomarker Could Predict Checkpoint Inhibitor Response in NSCLC Premium Mar 22, 2022 FDA Approves Merck's Keytruda for MSI-H, dMMR Endometrial Cancer With Roche CDx Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
